Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma

What happened: Junshi Biosciences said the first patient has been dosed in a phase 3 trial of JS203, an anti-CD20/CD3 bispecific antibody, combined with chemotherapy versus rituximab plus chemotherapy in relapsed or refractory DLBCL. Key numbers: Trial plans to enroll 282 subjects with overall survival as primary endpoint. Why it matters: This is the first registrational study for JS203. The study team cited encouraging early efficacy and a favorable safety profile as reinforcing confidence in the phase 3 trial.

Junshi Biosciences said the first patient has been dosed in a phase 3 trial of JS203, an anti-CD20/CD3 bispecific antibody, combined with chemotherapy versus rituximab plus chemotherapy in relapsed or refractory DLBCL.

This is the first registrational study for JS203. The study team cited encouraging early efficacy and a favorable safety profile as reinforcing confidence in the phase 3 trial.